Involvement of monoaminergic systems in the antidepressant-like effect of nobiletin

Physiology and Behavior

Volumn 102, Issue 1, 2011, Pages 1-6

  Yi, Li Tao ^a   Xu, He Li ^a   Feng, Jing ^a   Zhan, Xia ^a   Zhou, Li Pan ^a   Cui, Cun Cang ^a  

^a HUAQIAO UNIVERSITY   (China)

Author keywords

Antidepressant; Dopaminergic; Nobiletin; Noradrenergic; Serotonergic

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CYPROHEPTADINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NOBILETIN; PRAZOSIN; PROPRANOLOL; SULPIRIDE; YOHIMBINE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT EFFECT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTION; MALE; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; OPEN FIELD TEST; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; TAIL SUSPENSION TEST; TASK PERFORMANCE;

ADRENERGIC ANTAGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAZEPINES; CYPROHEPTADINE; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLAVONES; FLUOXETINE; HINDLIMB SUSPENSION; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PIPERAZINES; PRAZOSIN; PROPRANOLOL; PYRIDINES; SEROTONIN ANTAGONISTS; SULPIRIDE; SWIMMING; YOHIMBINE;

EID: 78049500586     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2010.10.008     Document Type: Article

References (59)

1. http://www.who.int/mental_health/management/depression/definition/en/.
2. Kulkarni S.K., Dhir A. Current investigational drugs for major depression. Expert Opin Investig Drugs 2009, 18:767-788.
3. Delgado P.L. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000, 61:7-11.
4. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:435-451.
5. Dailly E., Chenu F., Renard C.E., Bourin M. Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004, 18:601-607.
6. Matsuzaki K., Yamakuni T., Hashimoto M., Haque A.M., Shido O., Mimaki Y., et al. Nobiletin restoring beta-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. Neurosci Lett 2006, 400:230-234.
7. Onozuka H., Nakajima A., Matsuzaki K., Shin R.W., Ogino K., Saigusa D., et al. Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008, 326:739-744.
8. Yamamoto Y., Shioda N., Han F., Moriguchi S., Nakajima A., Yokosuka A., et al. Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation. Brain Res 2009, 1295:218-229.
9. Nakajima A., Yamakuni T., Haraguchi M., Omae N., Song S.Y., Kato C., et al. Nobiletin, a citrus flavonoid that improves memory impairment, rescues bulbectomy-induced cholinergic neurodegeneration in mice. J Pharmacol Sci 2007, 105:122-126.
10. Matsuzaki K., Miyazaki K., Sakai S., Yawo H., Nakata N., Moriguchi S., et al. Nobiletin, a citrus flavonoid with neurotrophic action, augments protein kinase A-mediated phosphorylation of the AMPA receptor subunit, GluR1, and the postsynaptic receptor response to glutamate in murine hippocampus. Eur J Pharmacol 2008, 578:194-200.
11. Takase H., Yamamoto K., Hirano H., Saito Y., Yamashita A. Pharmacological profile of gastric mucosal protection by marmin and nobiletin from a traditional herbal medicine, Aurantii fructus immaturus. Jpn J Pharmacol 1994, 66:139-147.
12. Binfaré R.W., Rosa A.O., Lobato K.R., Santos A.R., Rodrigues A.L. Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:530-540.
13. Gay B.M., Prigol M., Stein A.L., Nogueira C.W. Antidepressant-like pharmacological profile of 3-(4-fluorophenylselenyl)-2, 5-diphenylselenophene: involvement of serotonergic system. Neuropharmacology 2010, 59:172-179.
14. Tanaka M., Telegdy G. Involvement of adrenergic and serotonergic receptors in antidepressant-like effect of Urocortin 3 in a modified forced swimming test in mice. Brain Res Bull 2008, 77:301-305.
15. Yamada J., Sugimoto Y., Yamada S. Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol 2004, 504:207-211.
16. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Thér 1977, 229:327-336.
17. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
18. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
19. Racagni G., Popoli M. The pharmacological properties of antidepressants. Int Clin Psychopharmacol 2010, 25:117-131.
20. Pilkington K., Rampes H., Richardson J. Complementary medicine for depression. Expert Rev Neurother 2006, 6:1741-1751.
21. Fugh-Berman A., Cott J.M. Dietary supplements and natural products as psychotherapeutic agents. Psychosom Med 1999, 61:712-728.
22. Nagase H., Omae N., Omori A., Nakagawasai O., Tadano T., Yokosuka A., et al. Nobiletin and its related flavonoids with CRE-dependent transcription-stimulating and neuritegenic activities. Biochem Biophys Res Commun 2005, 337:1330-1336.
23. Bai F., Li X., Clay M., Lindstrom T., Skolnick P. Intra and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 2001, 70:187-192.
24. Steru L., Chermat R., Thierry B., Mico J.A., Lenegre A., Steru M., et al. The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 1987, 11:659-671.
25. Machado D.G., Bettio L.E., Cunha M.P., Capra J.C., Dalmarco J.B., Pizzolatti M.G., et al. Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:642-650.
26. Nakazawa T., Yasuda T., Ueda J., Ohsawa K. Antidepressant-like effects of apigenin and 2, 4, 5-trimethoxycinnamic acid from Perilla frutescens in the forced swimming test. Biol Pharm Bull 2003, 26:474-480.
27. Posser T., Kaster M.P., Baraúna S.C., Rocha J.B., Rodrigues A.L., Leal R.B. Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system. Eur J Pharmacol 2009, 602:85-91.
28. Bai F., Li X., Clay M., Lindstrom T., Skolnick P. Intra and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 2001, 70:187-192.
29. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
30. Delgado P.L., Moreno F.A. Antidepressants and the brain. Int Clin Psychopharmacol 1999, 14:9-16.
31. Nutt D.J. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008, 69:4-7.
32. Lambert G., Johansson M., Agren H., Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 2000, 57:787-793.
33. Esposito E. Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr Drug Targets 2006, 7:177-185.
34. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006, 110:135-370.
35. Stahl S.M. Essential psychopharmacology: neuroscientific basis and practical applications 2000, Cambridge University Press, Cambridge.
36. Heninger G.R., Delgado P.L., Charney D.S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996, 29:2-11.
37. Grimaldi B., Bonnin A., Fillion M.P., Prudhomme N., Fillion G. 5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety. Neuroscience 1999, 93:1223-1225.
38. Mayorga A.J., Dalvi A., Page M.E., Zimov-Levinson S., Hen R., Lucki I. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J Pharmacol Exp Ther 2001, 298:1101-1107.
39. Detke M.J., Wieland S., Lucki I. Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists. Psychopharmacology (Berl) 1995, 119:47-54.
40. Rosel P., Arranz B., San L., Vallejo J., Crespo J.M., Urretavizcaya M., et al. Altered 5-HT(2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims. Psychiatry Res 2000, 99:173-181.
41. Yates M., Leake A., Candy J.M., Fairbairn A.F., McKeith I.G., Ferrier I.N. 5HT2 receptor changes in major depression. Biol Psychiatry 1990, 27:489-496.
42. Goodnough D.B., Baker G.B. 5-Hydroxytryptamine2 and beta-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J Neurochem 1994, 62:2262-2268.
43. Ulak G., Mutlu O., Tanyeri P., Komsuoglu F.I., Akar F.Y., Erden B.F. Involvement of serotonin receptor subtypes in the antidepressant-like effect of trim in the rat forced swimming test. Pharmacol Biochem Behav 2010, 95:308-314.
44. Maj J., Klimek V., Nowak G. Antidepressant drugs given repeatedly increase binding to alpha 1-adrenoceptors in the rat cortex. Eur J Pharmacol 1985, 119:113-116.
45. Maj J., Rogóz Z., Dlaboga D., Dziedzicka-Wasylewska M. Pharmacological effects of milnacipran, a new antidepressant, given repeatedly on the alpha1-adrenergic and serotonergic 5-HT2A systems. J Neural Transm 2000, 107:1345-1359.
46. García-Sevilla J.A., Escribá P.V., Ozaita A., La Harpe R., Walzer C., Eytan A., et al. Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem 1999, 72:282-291.
47. Leonard B.E. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 1997, 7:S11-S16. [S71-3].
48. Handley S.L., Singh L. Chronic antidepressant treatment reduces central beta-adrenoceptor sensitivity in a behavioural test. Eur J Pharmacol 1986, 127:97-103.
49. De Paermentier F., Cheetham S.C., Crompton M.R., Katona C.L., Horton R.W. Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res 1990, 525:71-77.
50. Klimek V., Schenck J.E., Han H., Stockmeier C.A., Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry 2002, 52:740-748.
51. Heinz A., Schmidt L.G., Reischies F.M. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients-neurobiological correlates. Pharmacopsychiatry 1994, 27:7-10.
52. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997, 12:S7-S14.
53. Delini-Stula A., Radeke E., van Riezen H. Enhanced functional responsiveness of the dopaminergic system-the mechanism of anti-immobility effects of antidepressants in the behavioural despair test in the rat. Neuropharmacology 1988, 27:943-947.
54. Sibley D.R. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol 1999, 39:313-341.
55. Ossowska G., Nowak G., Klenk-Majewska B., Danilczuk Z., Zebrowska-Lupina I. Effect of imipramine on brain D-1 and 5-HT-2A receptors in a chronic unpredictable stress model in rats. Pol J Pharmacol 2002, 54:89-93.
56. Vaugeois J.M., Pouhé D., Zuccaro F., Costentin J. Indirect dopamine agonists effects on despair test: dissociation from hyperactivity. Pharmacol Biochem Behav 1996, 54:235-239.
57. Bressan R.A., Costa D.C., Jones H.M., Ell P.J., Pilowsky L.S. Typical antipsychotic drugs - D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002, 56:31-36.
58. Brown A.S., Gershon S. Dopamine and depression. J Neural Transm Gen Sect 1993, 91:75-109.
59. Renard C.E., Fiocco A.J., Clenet F., Hascoet M., Bourin M. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?. Psychopharmacology (Berl) 2001, 159:42-50.